NasdaqGS:TEMLife Sciences
Tempus AI (TEM) Joins CellCarta Network, Is The Stock Still Undervalued?
Tempus AI (TEM) stock is in focus after CellCarta Inc. added the company as the second commercial laboratory partner in its CDx Commercialization Lab Network for oncology companion diagnostics.
See our latest analysis for Tempus AI.
The CellCarta agreement has arrived alongside a sharp shift in momentum for Tempus AI, with the share price up 24.09% over the last day and a 30 day share price return of 26.52%, yet the 1 year total shareholder return has declined 16.42%. This suggests that...